You are here

PNH

Apellis takes the complement fight to Astrazeneca

Apellis takes the complement fight to Astrazeneca

EP Vantage

Flag link:

Apellis' Soliris rival gets a date at the FDA for a rare blood disorder, with potentially $400M worth of implications

Apellis' Soliris rival gets a date at the FDA for a rare blood disorder, with potentially $400M worth of implications

Endpoints

Flag link:

Novartis targets Alexion's fiefdom after showing PNH patients can safely switch from Soliris

Novartis targets Alexion's fiefdom after showing PNH patients can safely switch from Soliris

Fierce Biotech

clinical trials

Alexion Soliris

Flag link:

As CEO bounces back from Covid-19, Apellis says FDA meeting clears path to file for an OK on Soliris rival

As CEO bounces back from Covid-19, Apellis says FDA meeting clears path to file for an OK on Soliris rival

Endpoints

Flag link:

Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels

Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels

Reuters

Apellis Pharmaceuticals

Alexion Pharmaceuticals

Flag link:

Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms

Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms

Xconomy

Alexion Pharmaceuticals

Flag link:

After rocky hep C path, Achillion finds surer footing with FDA breakthrough status

After rocky hep C path, Achillion finds surer footing with FDA breakthrough status

Endpoints

paroxysmal nocturnal hemoglobinuria

Flag link:

Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?

Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?

Fierce Pharma

Flag link:

Alexion’s Soliris follow-up Ultomiris snares EU approval

Alexion’s Soliris follow-up Ultomiris snares EU approval

Pharmaforum

Flag link:

Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria

Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria

Pharmaceutical Business Review

Alexion Pharmaceuticals

Flag link:

4 Blockbuster Drug Launches to Watch in 2019

4 Blockbuster Drug Launches to Watch in 2019

Motley Fool

Alexion Pharmaceuticals

Aimmune Therapeutics

rheumatoid arthritis

Flag link:

Alexion runs toward big Ultomiris goals with early Soliris switching success

Alexion runs toward big Ultomiris goals with early Soliris switching success

Fierce Pharma

paroxysmal nocturnal hemoglobinuria

Flag link:

Alexion’s newly approved rare-disease drug notches another clinical trial win

Alexion’s newly approved rare-disease drug notches another clinical trial win

Stat

Alexion Pharmaceuticals

clinical trials

Flag link:

FDA approves new Alexion’s therapy targeting paroxysmal nocturnal hemoglobinuria

FDA approves new Alexion’s therapy targeting paroxysmal nocturnal hemoglobinuria

GoinPharma

Flag link:

Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris

Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris

Stat

Alexion Pharmaceuticals

Flag link:

FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria

FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria

CP Wire

Alexion Pharmaceuticals

paroxysmal nocturnal hemoglobinuria

Flag link:

Alexion's follow-on stacks up to Soliris

Alexion's follow-on stacks up to Soliris

Biopharma Dive

paroxysmal nocturnal hemoglobinuria

Flag link:

Akari CEO resigns amidst dodgy data claims

Akari CEO resigns amidst dodgy data claims

BioPharma Dive

Akari Therapeutics

clinical trials

Flag link:

The 'Soliris-killer' cometh? Alnylam plans final 2017 trials to take on world's priciest drug

The 'Soliris-killer' cometh? Alnylam plans final 2017 trials to take on world's priciest drug

BioPharma Dive

Flag link:

Alnylam Going After World's Most Expensive Drug in New Trials

Alnylam Going After World's Most Expensive Drug in New Trials

Bloomberg

Flag link:

Pages